Background: Surgical extraction of third molars is associated with postoperative pain and swelling at the extraction site. Pain is commonly managed using non-steroidal anti-inflammatory drugs (NSAIDs). Postoperative pain is usually moderate to severe in the first 12 h postoperatively and lasts for 3-5 days. However, with NSAIDs, these symptoms usually subside within 24 h. Diclofenac sodium and etodolac are NSAIDs, more selectively cyclooxygenase-2 inhibitors, with good analgesic efficacies. Methods: We compared the safety and analgesic efficacy of diclofenac sodium with etodolac peroral after surgical extraction of third molars in a double-blind, double-dummy, parallel-group study. The subjective pain improvement and pain relief after 2, 6, 24, 48, and 72 h using the visual analogue scale were measured as the study outcome. Results: Etodolac was equivalent to diclofenac sodium in pain alleviation at all postoperative time periods. No significant differences were found between diclofenac sodium and etodolac groups (P > 0.05). Both study medications were well tolerated and safe with mild adverse effects in only a few participants. Conclusion: Diclofenac sodium and etodolac are comparable in terms of analgesic efficacy and safety after surgical removal of third molars.
INTRODUCTION
Surgical extraction of third molars is associated with postoperative pain and swelling at the extraction site [1] .
Postoperative pain is usually moderate to severe in the first 12 h after the procedure and lasts for 3-5 days.
However, with non-steroidal anti-inflammatory drugs (NSAIDs), these symptoms usually subside within 24 h [2] . NSAIDs are the drug of choice for pain management after surgical extraction of third molars [3, 4] .
NSAIDs reduce prostaglandin production by inhibiting cyclooxygenase enzyme activity, thereby reducing the local inflammatory response and peripheral sensitization of nociceptors [5] . Diclofenac sodium, which is an NSAID with analgesic and antipyretic activities, inhibits prostaglandin synthesis [6] . It is among the most
METHODS
We procured diclofenac sodium from Unison Pharmaceuticals Private Limited, India, etodolac (Etogesic 400) from Cadila Healthcare Limited, India, and dummy preparations from Shri Sarvajanik Pharmacy College, Mehsana, Gujarat, India. This was a double-blind, doubledummy, randomized, parallel-group, split-mouth study.
The sample size for the study was estimated to be 100, with 95% power, 5% α-error, 10% drop-out rate, and an estimated difference between means of 0.65 [26] .
Inclusion criteria were as follows: 1) age between 18 and 60 years; 2) acute pain for less than 4 weeks; and 3) willingness to provide written informed consent.
Exclusion criteria were as follows: 1) a history of hypersensitivity to study drugs; 2) tooth injury; 3) acute pain for more than 4 weeks; 4) pregnancy or lactation; [29, 30] . Patients were followed-up for 3 days either in the outpatient department of dentistry or over the telephone for pain assessment and safety. If the study medications did not show an effect in 12-24 h, oral tramadol 100 mg stat and 4-6 hourly, as needed, was used for rescue analgesia. 16.00 ± 3.40 0.779 P-value < 0.0001* < 0.0001* n: number of participants; data are expressed as mean ± standard error of mean. Diclofenac sodium and etodolac groups were compared in terms of pain intensity at predetermined times using the Mann-Whitney U test (Table 2) , and results were not statistically significant (P > .05). Intragroup comparisons were performed using repeated analysis of variance. *= compared to preoperative value after any postoperative period. VAS = visual analogue scale Baseline characteristics (age, sex, and duration of surgery) were compared between the treatment groups.
P-values less than 0.05 were considered statistically significant. Data are expressed as mean ± standard error of mean. The mean time to analgesia at different time points and maximum pain relief were compared using the unpaired t-test or Mann-Whitney U test for an intergroup analysis and using the analysis of variance for an intragroup analysis. Patient global evaluation (excellent, very good, good, fair, or poor) was also performed. Statistical analyses was performed using GraphPad InStat trial version 3.06 (GraphPad Software Inc., San Diego, USA). Figure 1 showed the CONSORT flow diagram of patients in this trial. Table 1 shows the baseline characteristics of both treatment groups. The groups showed no significant differences in the baseline characteristics (P ˃ 0.05), duration of surgery, or baseline VAS score (P ˃ 0.05). Table 2 shows the comparison of pain intensity based on VAS scores between the two groups. N both groups, pain intensity reduced to half within 2 h postoperatively.
RESULTS
The VAS score reduced from 91. 36 the diclofenac group but in none of the patients in the etodolac group (P = 1.000). Table 3 shows the incidence of adverse reactions.
As the incidence of adverse reactions was low in both groups, both drugs may be considered safe and well tolerable. Table 4 shows the number of patients who required rescue analgesia. Pain intensity could not be controlled with study medications in three patients of the diclofenac group and two patients of the etodolac group (P = 1.000).
In these patients, tramadol 100 mg was orally administered. Table 5 shows the results of the patient global evaluation. Most participants reported the analgesic efficacy of the study medication to be "excellent"
or "good." Only a few participants reported a "very poor" evaluation.
DISCUSSION
In the present study, the safety and analgesic efficacy of diclofenac sodium and etodolac were compared In the present study, etodolac was as effective as diclofenac sodium in pain alleviation at all postoperative time periods, with no statistically significant difference.
The mean VAS score was 55.12 ± 3.75 in the diclofenac As pain intensity is maximum during the first 12 h, the rapid onset of analgesia in both groups reaffirmed the effectiveness of both drugs as good analgesics.
No statistically significant difference was found between the groups at any postoperative time period from baseline to 72 h postoperatively. At 2, 6, 8, 24, 48 and 72 h postoperatively, pain alleviation was estimated using the VAS score, which scaled down to 14.74 ± 3.45 in the diclofenac group and 16.00 ± 3.40 in etodolac group from the initial value to 72 h postoperatively (Fig. 2) . A statistically significant difference between baseline and 72-h VAS scores was found individually in both groups (P < 0.01).
Both drugs in this study were found to be safe and well tolerable with regard to adverse events. In the present study, two patients developed vomiting in each group, and one patient developed earache in the diclofenac group. Along with study medications, antacids, including tablet famotidine and capsule omeprazole, and antimicrobial drugs, including tablet amoxycillin-clavulanic acid and metronidazole were prescribed, so adverse reactions were less.
Rescue medication (tramadol 100 mg) was required for three patients in the diclofenac group and two patients in the etodolac group. Only a few participants required rescue analgesia, suggesting the safety of both study drugs. Tablet tramadol has been proven effective as an alternative to NSAIDs for orthopedic pain, so we used it as rescue medication [32] . No statistically significant difference was found between the groups with respect to the patient global evaluation [33] .
Akbulut N et al. reported that diclofenac sodium was a better analgesic compared to etodolac, although without statistical significance [26] . Diclofenac sodium and etodolac have been proven effective as an analgesic for pain associated with oral surgery, orthopedic disorders, and rheumatoid arthritis [34] [35] [36] . Silva et al. reported that etodolac is a better analgesic after surgical extraction of third molars compared to ibuprofen [19] . Etodolac has also been proven a better anti-inflammatory agent compared to other NSAIDs for some particular use [37] .
It has shown better gastrointestinal tolerability to diclofenac and other NSAIDs [34, 38] and has also been proven an effective alternative to diclofenac sodium in orthopedic pain [35] . An etodolac dose of 400 mg has been shown to have better analgesic effects compared to other doses postoperatively. Therefore, in the present study, a dose of 400 mg was administered [20] . Consistent with previous studies, this study showed etodolac to be equally effective in terms of pain alleviation. Our study also provided data on the postoperative use of etodolac as an analgesic in dentistry after surgical extraction of third molars.
In addition to pain, studies evaluating postoperative trismus and edema are underway. As our primary objective was to evaluate the safety and analgesic efficacy of etodolac, we did not evaluate trismus or edema. This can be considered as a limitation of our study. Furthermore, the effect of study medications in difficult surgeries was not evaluated because of the potential risk for bias.
As there is increased need of better and safer alternatives for pain relief after surgical extraction of third molars, etodolac can be a better alternative to diclofenac sodium.
Etodolac can be considered equally effective and safe as diclofenac sodium in terms of analgesic efficacy and safety after surgical extraction of third molars. 
